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ABBREVIATIONS 
 
ANP Atrial Natriuretic Peptide 
BCS Body Condition Score 
BNP B-type Natriuretic Peptide 
CHF Congestive Heart Failure 
IQR Inter Quartil Range 
MMVD Myxomatous Mitral Valve Disease 
NT-proANP N-terminal fragment of  pro-atrial Natriuretic Peptide 
NT-proBNP N-terminal fragment of  pro-B-type Natriuretic Peptide 
proANP 31-67 Pro-atrial Natriuretic Peptide 31-67 
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SUMMARY 
 
Measurement of plasma concentrations of natriuretic peptides have been suggested to be of 
diagnostic and prognostic value in canine cardiac disease. In several previous canine studies, 
however, a considerable overlap between investigated groups has been identified.  A reliable 
natriuretic peptide test for use in clinical practice requires establishment of reference values 
for natriuretic peptides in healthy dogs and cut-off values for subclinical disease as well as for 
clinical signs of congestive heart failure.  Numerous physiological, pathological and 
pharmacological factors, aside heart function, may influence concentration of natriuretic 
peptides. A potential effect of dog breed on natriuretic peptide concentration has been 
suggested but has, to our knowledge, not previously been specifically studied. Therefore, the 
aim of the present study was to investigate breed variation in plasma concentrations of 
natriuretic peptides in healthy dogs. 
 
Dogs of nine different breeds were examined at five different centers within the EU. A 
thorough clinical work-up was performed to exclude cardiovascular disease or other organ-
related or systemic disease. 535 healthy, privately-owned dogs were included. Blood samples 
were taken from all dogs, and plasma concentrations of proANP 31-67 and NT-proBNP were 
analyzed using commercially available ELISA assays. Samples were analyzed at two separate 
accredited laboratories, one for each peptide. 
 
The results showed an overall significant breed difference for proANP 31-67 (P<0.0001) as 
well as for NT-proBNP (P<0.0001). Pair-wise comparison between breeds showed significant 
differences in approximately 50% of the comparisons for both natriuretic peptides. Due to the 
uneven breed distribution between centers, group-wise comparisons between breeds were 
performed within each center, again resulting in significant differences in approximately 50% 
of the comparisons for both natriuretic peptides. The NT-proBNP concentration was 
associated with gender (R2 = 0.17, P<0.0001) with higher concentrations in female than male 
dogs. This result should, however, be interpreted cautiously due to uneven gender distribution 
between centers and high covariance between center, breed and gender. 
 
In conclusion, the study showed considerable breed variation in plasma concentration of 
natriuretic peptides in healthy dogs. Further studies are needed to establish breed-specific 
reference values.  
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SAMMANFATTNING 
 
Mätning av plasmakoncentration av natriuretiska peptider har föreslagits vara av diagnostiskt 
och prognostiskt värde för utvärdering av hjärtsjukdom hos hund. I flera tidigare studier har 
man dock sett en överlappning i uppmätta koncentrationer mellan olika undersökta grupper. 
För att ett test av natriuretiska peptider ska vara pålitligt för kliniskt bruk krävs fastställda 
referensvärden för natriuretiska peptider hos friska hundar samt gränsvärden för 
diagnosticering av hundar med subklinisk hjärtsjukdom respektive hjärtsvikt. Det finns dock 
ett stort antal fysiologiska, patologiska och farmakologiska faktorer, förutom hjärtsjukdom, 
som kan påverka plasmakoncentrationen av natriuretiska peptider. Det har föreslagits att 
hundras kan vara en sådan faktor men detta har till vår kännedom inte tidigare specifikt 
studerats. Syftet med studien var därför att undersöka rasvariation i plasmakoncentration av 
natriuretiska peptider hos friska hundar. 
 
Hundar av nio olika raser undersöktes vid fem olika center inom EU. En noggrann 
hälsoundersökning gjordes för att utesluta hjärtsjukdom eller annan organ-relaterad eller 
systemisk sjukdom. 535 friska, privatägda hundar inkluderades. Blodprover togs från alla 
hundar och plasmakoncentration av proANP 31-67 och NT-proBNP analyserades med 
kommersiella ELISA tester på två auktoriserade laboratorier, ett laboratorium för varje peptid. 
 
Resultaten visade signifikanta skillnader mellan raserna för proANP 31-67 (P<0.0001) och 
för NT-proBNP (P<0.0001). Parvisa rasjämförelser visade signifikanta skillnader i ungefär 
50% av jämförelserna för båda natriuretiska peptider. På grund av den ojämna 
rasfördelningen mellan centra, gjordes rasjämförelser även inom varje center. Återigen sågs 
signifikanta skillnader i ungefär 50 % av jämförelserna för de båda natriuretiska peptiderna. 
Koncentrationen av NT-proBNP var associerad med kön (R2 = 0.17, P<0.0001) med högre 
koncentrationer hos tikar än hanhundar, men detta resultat bör tolkas med försiktighet pga den 
ojämna könsfördelningen mellan centra samt den höga kovariansen mellan center, ras och 
kön. 
 
Sammanfattningsvis visade denna studie påtagliga skillnader i plasmakoncentration av 
natriuretiska peptider mellan raser. Ytterligare studier behövs för att fastställa rasspecifika 
referensvärden. 
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INTRODUCTION 
Background 
Heart disease in dogs is, in general practice, assessed by history of clinical signs, physical 
examination, auscultation of heart and lungs and radiographic imaging, despite the fact that it 
is difficult to make detailed assessments of the heart using these techniques (Oyama et al., 
2008, Prošek et al., 2007). More advanced diagnostic tools, such as echocardiography, are 
less accessible, because these methods require a trained clinician as well as expensive 
equipment (Oyama et al., 2008, Prošek et al., 2007). There are several reasons to strive for a 
simple, inexpensive and yet accurate blood test to help detect heart disease in dogs (Oyama et 
al., 2008, Prošek et al., 2007). In an acute clinical situation, it is important to quickly 
distinguish between clinical signs caused by heart disease, and similar clinical signs from 
afflictions unrelated to the heart (Oyama et al., 2007, Prošek et al., 2007). It would also be of 
great value to be able to monitor the progression of heart disease with the aim to accurately 
assess disease severity and optimize therapeutic intervention. In addition, because some forms 
of heart diseases can be hereditary, it would be beneficiary to be able to diagnose occult heart 
disease early to exclude affected dogs from breeding (Oyama et al., 2007).  
 
Introduction to natriuretic peptides 
DeBold et al discovered the first cardiac endocrine factor in 1981 when they found atrial 
natriuretic peptide (ANP) through experiments performed on rats. Their further investigations 
confirmed that ANP was produced by the heart and had diuretic, natriuretic and hypotensive 
abilities as well as an inhibitory effect on the renin-angiotensin-aldestorone system 
(Boomsma and van den Meiracker, 2001, de Bold, 1985, Maisel et al., 2008, Sudoh et al., 
1988). Brain natriuretic peptide (BNP) was originally isolated from porcine brain in 1988 by 
Sudoh et al. Structurally akin to ANP, with a sequence homology of 70%, BNP exhibits 
physiological effects that are very similar to the effects of ANP (Sudoh et al., 1988). It has 
later been established that BNP is primarily a cardiac peptide which is produced and secreted 
in a similar fashion to ANP, and it is now also known as B-type natriuretic peptide 
(Mukoyama et al., 1991, Sagnella, 2001, Saito et al., 1989, Yasue et al., 1994). There is a 
third member of the family, the C-type natriuretic peptide (CNP). It is structurally similar to 
ANP but is mainly produced in endothelium and has physiological actions that are distinct 
from ANP and BNP and will because of this not feature in this thesis (Boomsma and van den 
Meiracker, 2001, Koller and Goeddel, 1992, Sagnella, 2001, Wei et al., 1993). 
 
ANP and BNP both consist of one central disulphide ring of 17 amino acids with N-terminal 
and C-terminal segments that have variable lengths (Koller and Goeddel, 1992, Sagnella, 
2001). They are synthesized as high molecular weight precursors, pro-hormones, which are 
cleaved into two segments (Saito et al., 1989, Yasue et al., 1994). One low molecular weight, 
biologically active segment in the C-terminal region; described as  ANP or BNP, and one 
biologically inactive N-terminal segment; described as NT-proANP or NT-proBNP (Maisel et 
al., 2008, Saito et al., 1989, Thibault et al., 1987, Yasue et al., 1994) . NT-proANP is then 
further cleaved into three segments, proANP 1-30, 31-67 and 68-98 (Winters et al., 1989). 
ANP and BNP both bind to the A-type natriuretic peptide receptor which activates guanylyl 
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cyclase, leading to the formation of the intercellularly active cyclic guanosine monophosphate 
(cGMP) and thereby evoking cellular response (Boomsma and van den Meiracker, 2001, 
Koller and Goeddel, 1992). There are two ways of clearance. All of the segments are cleared 
by enzymatic degradation by neutral endopeptidase and for the biologically active ANP and 
BNP, there is also a specific clearance receptor (Boomsma and van den Meiracker, 2001). 
Inactive segments have a longer half-life and longer lasting plasma concentrations because 
they do not have a specific clearance receptor (Boomsma and van den Meiracker, 2001, 
Buckley et al., 1999, Morgenthaler et al., 2004).  
 
The main cause of production and release of natriuretic peptides is an increase in stretch 
and/or pressure in the myocardial wall, although it is worth noting that angiotensin and 
endothelin are also thought to be influential (Boomsma and van den Meiracker, 2001, 
Luchner et al., 2000, Yasue et al., 1994). ANP is stored in secretion granules in the 
myocardial wall, mainly in high molecular mass precursor form, and there is no increase in 
gene expression in response to myocardial stretch (Mantymaa et al., 1993, Sagnella, 2001). 
BNP is constitutively secreted and has little intracellular storage, and its gene expression is 
increased in response to myocardial stretch (Mantymaa et al., 1993, Sagnella, 2001). In 
healthy humans, ANP is secreted mainly from the atrial tissue and BNP mainly from the left 
ventricle (Mukoyama et al., 1991). Canine ANP is produced mainly in the atrium as in 
humans, but in canines the main BNP production is also in the atrial myocardium in the 
healthy heart (Luchner et al., 1998, Yasue et al., 1994). In CHF, however, ventricular 
production of ANP and BNP is activated in response to stretching of ventricular myocardial 
walls (Luchner et al., 1998, Luchner et al., 2000). Davis et al (1994) was the first to report 
that an increase in plasma concentration of BNP could be used as an indicator of heart failure 
in humans. Further study on humans led to the discovery that the secretion of ANP and BNP 
from the myocardial wall rises proportionally to cardiac dysfunction (Yasue et al., 1994). 
Häggström et al (1994) was first to report a rising concentration of plasma ANP in dogs with 
increasing  heart disease severity, and Asano et al (1999) concluded early that ANP and BNP 
could be useful in diagnosing CHF in dogs. Plasma concentrations of N-Terminal segments 
have also been shown to correlate with heart size and systolic function in dogs (Oyama et al., 
2007, Oyama et al., 2008).  
Tests 
Early tests for measuring natriuretic peptides in humans and dogs concentrated on ANP and 
BNP analysis (Boswood et al., 2008, Sagnella, 2001). In the beginning specific radio immune 
assays (RIAs) were used and by the late 1990s, immunoradioassay (IRMA) was developed 
(Boswood et al., 2008, Sagnella, 2001). The aminoacid sequences in human and canine 
natriuretic peptides are different which makes it difficult to use human assay methods for 
measuring canine natriuretic peptides (Boswood et al., 2008). This difference is greater for 
BNP and NT-proBNP than for ANP and NT-proANP to the extent that a human test may be 
used for canine NT-proANP, but a specific canine test needs to be used for canine NT-
proBNP (Boswood et al., 2008, O'Sullivan et al., 2007). Canine specific competitive enzyme-
linked immunosorbent assays (ELISA) for ANP and BNP, respectively, are now in use 
(DeFrancesco et al., 2007).  
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It is widely accepted that increased blood concentrations of ANP,  BNP, NT-proANP and 
NT-proBNP are all indicative of heart disease in both dogs and humans (Oyama et al., 2007, 
Oyama et al., 2008, Sagnella, 2001). There has been a lot of discussion as to which peptide 
(ANP or BNP) and which segment (biologically active or inactive form) is the best for 
evaluating or diagnosing heart disease (Sagnella, 1998). Different forms might be better for 
different heart afflictions, and since the inactive segments have been found to have longer  
half-life than the biologically active segments; they may be better suited as diagnostic tools 
(Buckley et al., 1999, Morgenthaler et al., 2004, Pemberton et al., 2000, Sagnella, 1998). 
 
When compared to ANP, BNP has been shown to have greater sensitivity and specificity as 
an indicator of heart failure in humans as well as in dogs (Cowie et al., 1997, Oyama et al., 
2007). BNP also has better characteristics for a screening test (Cowie et al., 1997, O'Sullivan 
et al., 2007). It has both greater specificity and sensitivity than ANP, for several different cut-
off values, and has also shown a higher predictive value (Chetboul et al., 2004, Cowie et al., 
1997). As for practicality as a clinical test, BNP has better stability in whole blood in room 
temperature than ANP (Cowie et al., 1997). 
 
BNP and NT-proBNP have different half-lives, modes of degradation and cut-off values 
(Maisel et al., 2008, Sagnella, 1998). The half-life for BNP in dogs is 1.5 minutes, compared 
to 22 minutes in humans (Thomas and Woods, 2003). To our knowledge, the half-life of NT-
proBNPs in dogs has not been determined, but in sheep it has been shown to be 15 times 
longer than that of BNP (Pemberton et al., 2000). The inactive segments of proANP have also 
been shown to have longer half-lives than ANP in humans (Buckley et al., 1999, 
Morgenthaler et al., 2004). A short half-life in a peptide might indicate that significant 
degradation can occur before it can be measured; hence the inactive fragments might be better 
as diagnostic tools in dogs. BNP might however be better suited for detecting short-term 
changes than NT-proBNP (Oyama et al., 2008). When compared to NT-proBNP tests, BNP 
tests need specialized collection and handling which makes NT-proBNP testing easier to 
execute (Oyama et al., 2008). 
 
Natriuretic peptides today 
In the year 2000, the Food and Drug Administration (FDA) approved BNP as an aid in the 
diagnosis of human heart failure. BNP and NT-proBNP tests are currently widely used in 
human medicine for diagnosis, risk stratification and therapeutic decision making in acute 
coronary syndromes, hypertension, pulmonary embolism and early detection of ventricular 
and atrial myocardial dysfunction that might lead to heart failure (Boomsma and van den 
Meiracker, 2001, Maisel et al., 2004, Maisel et al., 2008). In the diagnosis of acute CHF, a 
quick result is crucial and so called bedside tests are used (Maisel et al., 2004, Maisel et al., 
2008). There are no bedside tests available for dogs as of yet, and natriuretic peptide assay is 
not yet standard in veterinary practice (Ettinger et al., 2012). However, elevated plasma 
concentrations of natriuretic peptides have been identified in dogs with dilated 
cardiomyopathy (DCM) (Haggstrom et al., 2000, O'Sullivan et al., 2007, Oyama et al., 2007, 
Oyama et al., 2008, Singletary et al., 2012, Wess et al., 2011). In dogs with myxomatous 
mitral valve disease (MMVD), concentrations of natriuretic peptides have been shown to 
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increase, partly depending on disease severity (Oyama et al., 2008, Takemura et al., 2009, 
Tarnow et al., 2009, Wolf et al., 2012), and NT-proBNP has been shown predicative of 
outcome in dogs with MMVD (Reynolds et al., 2012, Tarnow et al., 2009). Natriuretic 
peptides have also been found useful to distinguish CHF from respiratory disease (Boswood 
et al., 2008, DeFrancesco et al., 2007, Prošek et al., 2007, Reynolds et al., 2012). To have a 
relevant diagnostic and prognostic test for heart disease, it is necessary to establish an upper 
reference limit for natriuretic peptides in healthy individuals,  and cut-off values for clinical 
signs of heart disease (Ettinger et al., 2012, Sagnella, 1998). A considerable overlap between 
concentrations in investigated groups has however been identified between and within several 
of the canine studies.  
Influencing factors 
There are numerous  physiological, pathological, pharmacological, biochemical and 
hematological factors besides heart function that may influence the levels of natriuretic 
peptides in humans as well as in dogs (Balion et al., 2008, Boswood et al., 2008, DeFrancesco 
et al., 2007, Ettinger et al., 2012, Kellihan et al., 2009, O'Sullivan et al., 2007, Oyama et al., 
2008, Prošek et al., 2007, Takemura et al., 2009, Tarnow et al., 2009). In a review article, 
Balion et al (2008) list no fewer than 103 factors that affect human BNP or NT-proBNP. 
Another important consideration is that natriuretic peptides are involved in several different 
physiological processes in the body and their levels may be affected by several different 
factors (Balion et al., 2008). There are concerns of how to adjust reference limits and cut-off-
values in regard to the large number of affecting factors in humans as well as in dogs (Balion 
et al., 2008, Boswood et al., 2008, DeFrancesco et al., 2007, Ettinger et al., 2012, Kellihan et 
al., 2009, Oyama et al., 2008, Prošek et al., 2007, Takemura et al., 2009, Tarnow et al., 2009, 
O'Sullivan et al., 2007). In addition, the ideal sensitivity and specificity for a test is still 
debated (Ettinger et al., 2012, Kellihan et al., 2009, Maisel et al., 2008, Singletary et al., 
2012). 
 
Age is an important influential physiological factor in humans, potentially caused by 
decreased heart function with greater age (Balion et al., 2008). According to Balions et al 
(2008) review article, age was positively associated with both BNP and NT-pro-BNP in 80 % 
of the reviewed studies. However, the majority of studies performed on dogs did not find an 
association between natriuretic peptide plasma concentration and age  (Boswood et al., 2008, 
DeFrancesco et al., 2007, Eriksson et al., 2001, Kellihan et al., 2009, Oyama et al., 2007, 
Oyama et al., 2008, Tarnow et al., 2009). In the few canine studies that did find an 
association, it was suggested that the association could be caused by the higher incidence of 
heart disease in older male dogs (DeFrancesco et al., 2007, Eriksson et al., 2001, Ettinger et 
al., 2012, O'Sullivan et al., 2007). Women had a higher concentration of plasma BNP than 
men in around 50% of human studies (Balion et al., 2008). Most canine studies that included 
gender and reproductive status did not find an association (Boswood et al., 2008, 
DeFrancesco et al., 2007, Eriksson et al., 2001, Ettinger et al., 2012, Oyama et al., 2008, 
Tarnow et al., 2009), but one study found a positive association between ANP and age 
(O'Sullivan , et al., 2007). In humans, body weight has been shown to correlate inversely with 
plasma concentration of natriuretic peptides possibly caused in part by progressive weight 
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loss in connection with heart disease (Chen-Tournoux et al., 2010, Eriksson et al., 2001). 
Canine studies show conflicting results (Eriksson et al., 2001, Ettinger et al., 2012, Kellihan 
et al., 2009, Tarnow et al., 2009). The individual weekly variability of plasma NT-pro-BNP 
concentration has been found to be considerable for humans as well as for dogs (Kellihan et 
al., 2009, O'Hanlon et al., 2007, Oyama et al., 2008).  
 
To our knowledge, variation in natriuretic peptide concentration between dog breeds has not 
previously been specifically studied. However, significantly higher serum concentration of 
NT-proBNP has been found in healthy pure-breed dogs compared to concentrations in healthy 
mixed-breed dogs (Oyama et al., 2008). The possibility of biological differences in 
production, release and clearance of NT-proBNP between breeds has been suggested (Oyama 
et al., 2008). Hence, the aim of the present study was to investigate breed variation in plasma 
concentrations of natriuretic peptides in healthy dogs. 
 
 
 
MATERIALS AND METHODS 
Animals 
To be included in the study, dogs had to be pure-bred, healthy, and between 1 and 7 years of 
age. These dogs had been found healthy, which in this study entailed passing a general health 
examination with no abnormal findings, no ECG abnormalities were detected, and all 
echocardiographic variables were within reference values. Furthermore, no clinically 
significant abnormalities were detected in the hematological or blood biochemistry variables. 
They also had to have a normal body condition score, and could not be related to each other at 
parental level. Dogs were examined at five different centers, as part of the EU funded LUPA-
project (Lequarre et al., 2011). Centers included University of Liège, Belgium; University of 
Copenhagen, Denmark; National Veterinary School of Alfort, France; University of Helsinki, 
Finland and the Swedish University of Agricultural Sciences, Sweden. The study was 
approved by an ethical committee in each participating country. Dogs were privately-owned 
and informed owner consent was obtained. Each cohort included dogs of one gender only, 
either intact males or females which were spayed or in anestrus. Exclusion criteria consisted 
of any finding indicating systemic or organ related disease observed at the clinical 
examination outlined below. 
 
Preparations 
Dog owners were instructed to solely feed their dog standard commercial dog food two weeks 
prior to participation in the study to avoid uneven or excessive salt intake.  On examination 
day, all dogs were fasting and had no access to water for at least two hours before the 
examination. 
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Verification of health status 
Each dog underwent a general physical examination including blood pressure measurement 
by high-definition oscillometry, a five minute ECG registration and an echocardiographic 
examination. The echocardiographic examination was performed from the right and left side 
using standardized imaging planes (Thomas and Woods, 2003) and continuous ECG-
monitoring. The left atrial to aortic root ratio was quantified from the right two-dimensional 
short-axis view (Hansson et al., 2002). Pulmonic and aortic flow velocities were measured by 
spectral Doppler, and the mitral, aortic, pulmonic and tricuspid valves were screened using 
color Doppler. The left ventricle was measured using standard M-mode techniques. Urine 
samples were collected by natural micturition and standard urine analysis was performed by 
dipstick and refractometer.  Blood sampling was carried out by venipuncture and blood was 
collected into 5-mL EDTA- and serum tubes. Analysis of hematology and biochemistry 
regarding liver and kidney variables, glucose and electrolytes were performed. 
 
Analysis of natriuretic peptides 
Concentrations of proANP 31-67 and NT-proBNP were measured in plasma.  EDTA-tubes 
were centrifuged within 30 minutes of blood sample collection. Plasma was harvested, 
transferred into plastic cryotubes and samples were frozen. Samples were stored at -80°C. At 
one center, samples were, for practical reasons, stored at -20°C for a maximum of 2 weeks, 
where after they were transferred frozen to -80°C and stored for batched analysis. Previous 
studies have shown that midregional proANP is stable for 3-6 months at -20°C and NT-
proBNP is stable for 4 months at -20°C (Hunt et al., 1997, Morgenthaler et al., 2004, Mueller 
et al., 2004).  All samples were later transported frozen to two accredited laboratories, which 
analyzed concentrations of proANP 31-67 and NT-proBNP, respectively, using commercially 
available ELISA assays1,2. All samples were analyzed in duplicate and the mean of the two 
samples were used for data analysis.  
 
 
Statistical analysis 
Commercially available software3 was used for all statistical analyses. Data is presented as 
medians and interquartile ranges (IQR). A value of P < 0.05 was considered significant for 
the analysis, unless otherwise indicated.  
 
The non-parametric Kruskal-Wallis test was used to investigate overall differences between 
breeds, in concentrations of proANP 31-67 and NT-proBNP, respectively. If a significant 
difference was detected, pair-wise comparisons between breeds were performed by use of the 
Mann Whitney U-test with Bonferroni adjustment, for which a value of P < 0.0014 was 
considered significant. The Kruskal-Wallis test was also used to investigate differences 
between breeds within each center, for concentrations of proANP 31-67 and NT-proBNP, 
respectively. In centers including more than two breeds, pair-wise comparisons between 
                                                  
1  NT-proBNP: ELISA Cardiopet proBNP test (IDEXX Laboratories, Westbrook, Maine, USA) 
2  ProANP 31-67: ELISA VETSIGN Canine CardioSCREEN (Biomedica, Vienna, Austria) 
3 JMP, version 9.0.0, SAS Institute Inc, Cary, NC, USA 
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breeds were performed by use of the Mann Whitney U-test with Bonferroni adjustment, if an 
overall significant difference was detected.  
 
Unilinear regression analyses were performed to evaluate potential associations between 
breed as well as age, gender, body weight, examination center, and concentrations of proANP 
31-67 and NT-proBNP, respectively. A subanalysis of the same variables by unilinear 
regression analysis was performed in the Labrador retriever breed alone, since it included the 
largest number of dogs, was represented at four out of five centers and included both female 
and male dogs. 
 
To compensate for other confounding factors for the breed variable on plasma concentration 
of natriuretic peptides, a multiple regression analysis was performed, including variables 
which reached P < 0.2 in the unilinear regression analysis. Analyses were performed in a 
reverse stepwise manner  (Bland, 1995), starting with all variables included in the model and 
then removing the variable with the highest P-value until all remaining variables had a value 
of P < 0.05. All variables were assessed only as main effects; no interaction terms were 
considered in the model.  
 
The distribution of residuals in the multiple-regression analysis was tested for normality using 
Shapiro Wilk W test. The adjusted R2 is defined as the percentage of the total sum of squares 
that can be explained by the regression and it also considers the degrees of freedom for 
variables added. No multiple regression analysis was performed in the Labrador retriever 
cohort, due to the high covariance between center and gender.  
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RESULTS 
Distribution 
In total, 535 dogs of nine breeds were included in the study. Distribution of breeds and 
individuals examined at the different centers are shown in table 1. Each center examined dogs 
belonging to 2-4 different breeds, some breeds were shared between centers. Gender 
distribution was uneven with 416 male and 119 female dogs (Table 1). All males were intact 
while females were spayed or in anoestrus. Median age (n = 531) was 3.3 (IQR 2.6-4.4) years 
and median body weight (n = 497) was 30.2 (IQR 23.5-36.0) kg. 
 
 
Table 1. Distribution by center of examination, breed, and gender 
 Belgium Denmark Finland France Sweden Total 
Box     15M 15 
BS 97M   26M  123 
CKCS      34M 34 
Dach   26M  16M 42 
Dob    25M  25 
FinL   50M   50 
GS 16M  60M   76 
Lab 6M 45F  29F 45M 125 
NF  45F    45 
Total 119 90 136 80 110 535 
Box = Boxer, BS = Belgian Shepherd, CKCS = Cavalier King Charles Spaniel, Dach = Dachshund, 
Dob = Doberman, FinL = Finnish Lapphund, GS = German Shepherd, Lab = Labrador Retriever, 
NF= Newfoundland. M = male, F = female 
 
 
Natriuretic peptides 
The median concentration of proANP 31-67 (n = 535) was 889 (IQR 735-1065) pmol/L, 
while the median concentration of NT-proBNP (n = 527) was 638 (IQR 403-980) pmol/L. 
Natriuretic peptide concentrations by breed are shown in Figure 1 and Figure 2. 
Group wise comparisons, all dogs 
There was an overall significant breed difference for proANP 31-67 (P<0.0001) and NT-
proBNP (P<0.0001). Pair-wise comparisons between breeds showed significant differences 
for 15 of 36 comparisons of proANP 31-67 and 18 of 36 comparisons of NT-proBNP (Table 
3). Concentrations of proANP 31-67 were lowest in Doberman Pinschers, with a median 
value almost half of the values in German Shepherds and Cavalier King Charles Spaniels, 
which had the highest concentrations (Figure 1). Concentrations of NT-proBNP were lowest 
in Dachshunds, whereas Labrador Retrievers and Newfoundlands had the highest 
concentrations with median values of three times the median concentration in Dachshunds 
(Figure 2). 
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 ProANP 31-67 by breed 
 
 
Figure 1. Boxplot showing distribution of proANP 31-67 by breed. The top, bottom and line through 
the middle of the box correspond to the 75th percentile (top quartile), the 25th percentile (bottom 
quartile) and the 50th percentile (median), respectively. The whiskers extend from the bottom 10th 
percentile (bottom decile) to the top 90th percentile (top decile). Outliers, represented by black dots, 
show the highest and lowest individual concentrations. Outliers were not excluded from the statistical 
analyses. There was an overall significant difference between breeds (P< 0.0001). For information of 
which breeds that differed significantly, see table 5. Box = Boxer, BS = Belgian Shepherd, CKCS = 
Cavalier King Charles Spaniel, Dach = Dachshund, Dob = Doberman, FinL = Finnish Lapphund, GS 
= German Shepherd, Lab = Labrador Retriever, NF= Newfoundland 
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NT-proBNP by breed 
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Figure 2. Boxplot showing distribution of NT-proBNP by breed. The top, bottom and line through the 
middle of the box correspond to the 75th percentile (top quartile), the 25th percentile (bottom quartile) 
and the 50th percentile (median), respectively. The whiskers extend from the bottom 10th percentile 
(bottom decile) to the top 90th percentile (top decile). Outliers, represented by black dots, show the 
highest and lowest individual concentrations. Outliers were not excluded from the statistical analyses. 
There was an overall significant difference between breeds (P-value 0.0001). For information of 
which breeds that differed significantly, see table 5. Box = Boxer, BS = Belgian Shepherd, CKCS = 
Cavalier King Charles Spaniel, Dach = Dachshund, Dob = Doberman, FinL = Finnish Lapphund, GS 
= German Shepherd, Lab = Labrador Retriever, NF= Newfoundland 
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Plasma concentrations of natriuretic peptides by breed 
Table 2. Plasma concentrations of natriuretic peptides by breed, median values and inter quartil 
range (IQR) (pmol/L) 
 proANP 31-67  NT-proBNP 
Breed n= Median IQR  n= Median IQR 
Box 15 771 640-917  15 506 387-720 
BS 123 853 705-1067  122 521 360-863 
CKCS  34 1001 850-1159  34 561 373-1016 
Dach 42 786 609-846  42 303 220-440 
Dob 25 571 497-638  25 452 224-937 
FinL 50 930 816-1045  50 650 399-791 
GS 76 1034 844-1231  75 691 446-1063 
Lab 125 898 791-1073  119 931 616-1314 
NF 45 905 790-999  45 935 654-1259 
Box = Boxer, BS = Belgian Shepherd, CKCS = Cavalier King Charles Spaniel, Dach = Dachshund, 
Dob = Doberman, FinL = Finnish Lapphund, GS = German Shepherd, Lab = Labrador Retriever, 
NF= Newfoundland.  
 
 
Pair wise breed comparison 
Table 3. Pair-wise comparisons between breeds in plasma concentrations of natriuretic peptides 
showing the significant P-values for each peptide 
 Box CKCS Dach Dob FinL GS Lab NF  
BS    
<.0001  0.0008   proANP 31-67 
  <.0001    <.0001 <.0001 NT-proBNP 
 Box 
0.0014    0.0004    proANP 31-67 
 0.0013    <.0001 0.0002 NT-proBNP 
  CKCS 
<.0001 <.0001     proANP 31-67 
 <.0001    <.0001 <.0001 NT-proBNP 
   Dach 0.0002 <.0001 <.0001 <.0001 0.0002 proANP 31-67    <.0001 <.0001 <.0001 <.0001 NT-proBNP 
    Dob 
<.0001 <.0001 <.0001 <.0001 proANP 31-67 
     0.0002 0.0009 NT-proBNP 
     FinL    
proANP 31-67 
     <.0001 <.0001 NT-proBNP 
      GS   
proANP 31-67 
     0.0006  NT-proBNP 
       Lab  proANP 31-67        NT-proBNP 
 
Box = Boxer, BS = Belgian Shepherd, CKCS = Cavalier King Charles Spaniel, Dach = Dachshund, 
Dob = Doberman, FinL = Finnish Lapphund, GS = German Shepherd, Lab = Labrador Retriever, 
NF= Newfoundland 
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Group wise comparisons, within center 
Overall significant breed differences were found within three of the five centers for proANP 
31-67 (P≤0.0006) and four of five centers for NT-proBNP (P<0.003). Pair-wise comparisons 
showed significant differences for 8 of 16 comparisons of proANP 31-67 and 7 of 16 
comparisons of NT-proBNP.  
Unilinear regression analysis 
In the unilinear regression analysis of all dogs (Table 4), an association was shown between 
proANP 31-67 and breed, as well as center of examination. NT-proBNP was also associated 
with breed and center of examination. Furthermore, NT-proBNP was associated with 
increasing body weight and with gender, where higher concentrations were found in female 
than in male dogs. In the separate unilinear regression analysis of Labrador retrievers (Table 
5), an association was shown between proANP 31-67 and center of examination, as well as 
gender, with higher concentrations in male than female dogs. NT-proBNP was associated 
with center of examination and gender, with higher concentrations in female than male dogs 
(Table 5), (Figure 3). 
 
 
 
 
Table 4. Significant outcomes in the unilinear regression analysis of all dogs. An empty space 
indicates that no significant association was found 
 proANP 31-67 NT-proBNP 
 R2 P-value R2 P-Value 
Body weight   0.04 <0.0001 
Breed 0.15 <0.0001 0.16 <0.0001 
Center of examination 0.07 <0.0001 0.16 <0.0001 
Gender   0.17 <0.0001 
 
 
 
 
Table 5. Significant outcomes in the separate unilinear regression analysis of Labrador Retriever 
cohorts. An empty space indicates that no significant association was found 
 proANP 31-67 NT-proBNP R2 P-value R2 P-Value 
Age     
Center of examination 0.11 0.003 0.24 <0.0001 
Gender 0.05 0.01 0.24 <0.0001 
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NT-proBNP in Labrador retrievers by gender 
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Figure 3. Boxplot showing the NT-proBNP concentration in female (n=68) and male (n=51) Labrador 
Retriever dogs. The top, bottom and line through the middle of the box correspond to the 75th 
percentile (top quartile), the 25th percentile (bottom quartile) and the 50th percentile (median), 
respectively. The whiskers extend from the bottom 10th percentile (bottom decile) to the top 90th 
percentile (top decile). Outliers, represented by black dots, show the highest and lowest individual 
concentrations. Outliers were not excluded from the statistical analyses.  (F = females, M = males) 
 
Multiple regression analysis 
The multiple regression analysis of all dogs confirmed an effect of breed (P<0.0001) and 
center (P = 0.0008) on proANP 31-67 concentration with an adjusted model R2 of 0.16. Also 
for NT-proBNP concentration, multiple regression analysis confirmed an effect of breed 
(P<0.0001) and center (P<0.0001) with an adjusted model R2 of 0.22. 
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DISCUSSION 
The main findings of this study were highly significant overall breed differences in plasma 
concentrations of proANP 31-67 and NT-proBNP in healthy dogs examined at five centers. 
Significant differences were found in approximately fifty percent of the pair-wise 
comparisons between breeds for proANP 31-67 as well as for NT-proBNP concentrations, 
when including all centers and also within each center. Among the nine breeds included in the 
study, Labrador Retrievers and Newfoundlands had the highest median NT-proBNP 
concentrations with values three times as high as Dachshunds. Interestingly, in the case of 
proANP 31-67, it was instead German Shepherds and Cavalier King Charles Spaniels that had 
the highest median concentrations, which were twice the median concentration in Doberman 
Pinschers, which had the lowest concentrations. This might be indicative of breed differences 
in the interrelationship between NT-proBNP and proANP 31-67, potentially due to breed 
differences in production, release and/or clearance. 
 
A strong selection for certain physiological, morphological and behavioral traits has created 
dog breeds with a unique diversity among mammalian species, and specific features are 
inherited closely within a breed (Parker and Ostrander, 2005). The breeds included in the 
present study represent dogs of varying body sizes, temperament, utilities, and genetic 
background. Breed differences in, for example, blood pressure, heart rate, and catecholamine 
concentrations have been found in previous studies, and potential connections to differences 
in temperament and reactivity pattern in the sympathetic nervous system have been suggested 
(Bodey and Michell, 1996, Hansson et al., 2002, Hoglund et al., 2012, Rasmussen et al., 
2011). 
 
Center of examination was associated with plasma concentration of both proANP 31-67 and 
NT-proBNP in the unilinear as well as multiple regression analyses. Due to the uneven breed 
distribution between centers, center was highly covariate with breed, and additional group-
wise comparisons were performed between breeds within each center. The results showed a 
similar percentage of significant pair-wise differences as when all dogs were included 
(approximately fifty percent for both natriuretic peptides), thus confirming the presence of 
breed variation in the examined population. 
 
Higher concentrations of NT-pro BNP in female than in male dogs were shown in the 
statistical analysis of all dogs.  An association between gender and concentration of NT-pro 
BNP was shown in the unilinear regression analysis, but not in the multiple regression 
analysis. Pro-ANP 31-67 was not associated with gender in the unilinear or multiple 
regression analysis of all dogs. Since each cohort, according to the study protocol, included 
only dogs of the same gender, the gender distribution in this study was uneven (Table 1). To 
further investigate the effect of gender, a subanalysis of all Labrador Retrievers was 
performed, as this was the breed with the most even gender distribution. Furthermore, this 
breed had the highest number of individuals and was represented at four out of the five 
centers of examination. In the unilinear regression analysis of the Labrador Retrievers, the 
association between gender and concentration of NT-pro BNP was confirmed and higher 
concentrations in female dogs were shown. Slightly higher concentrations of pro-ANP 31-67 
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were found in Labrador Retriever males compared to females. The association was, however, 
very weak. Due to the uneven gender distribution between centers of examination, our results 
on gender differences need to be interpreted cautiously and further studies are needed to 
assess a potential effect of gender on natriuretic peptide concentration in dogs. 
 
In the present study, no association between age and natriuretic peptide concentration was 
found which is in accordance with the majority of previous canine studies. However, the 
present study only included young adult to middle aged dogs, thereby excluding dogs of older 
age in which increased concentrations of natriuretic peptides have been suggested by a few 
previous studies (DeFrancesco et al., 2007, Eriksson et al., 2001). Further studies are needed 
to investigate a potential association between age, and natriuretic peptide concentration in 
healthy dogs. 
 
No association was found between proANP 31-67 or NT-proBNP and body weight in the 
multiple regression analysis in the present study. However, there was a weak positive 
association with NT-proBNP in the unilinear regression analysis. This is not in accordance 
with the few canine studies that have found an association, in which the associations were 
negative. However, this has been suggested to be caused by progressive weight loss in 
connection with heart disease, and because our study population only consisted of healthy 
dogs with a normal body condition score this does not apply to the present study (Eriksson et 
al., 2001). In the subanalysis of Labrador retrievers, body weight was not associated with 
proANP 31-67 or NT-proBNP.  
 
For successful use of natriuretic peptides as diagnostic tools in clinical practice, reference 
values for healthy individuals as well as cut-off values for cardiac disease need to be 
established. The dogs included in the present study were confirmed healthy by an extensive 
health examination and yet the present study shows, in addition to variation between breeds, 
large variations within breeds. To adjust cut-off points in regard to the numerous influential 
factors is not straightforward. When compared to reference values suggested by a recent study 
using the same assay, several individuals in our study were shown to have NT-proBNP 
concentrations equivalent to, or higher than values proposed indicative of heart disease in 
dogs (Ettinger et al., 2012). In some breeds, a large share of healthy individuals had NT-
proBNP concentrations higher than the suggested reference values, and in other breeds, the 
major part of individuals were markedly below.  
 
Breed specific guidelines and cut-off points should, in light of the findings of this study, be 
set according to breed variation (DeFrancesco et al., 2007, Eriksson et al., 2001, Oyama et al., 
2007, Oyama et al., 2008). Further research on natriuretic peptides in dogs should preferably 
be performed on breed matched cohorts. Measurement of plasma natriuretic peptides should 
not, even when commercially available as a bedside test, be used as a sole diagnostic tool but 
as an aid in combination with other diagnostic tools. 
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Study limitations 
The study only included nine breeds and therefore the results cannot be considered 
representative for the entire dog population. Due to the uneven gender representation and 
narrow age span of included dogs, results should not been seen as reference values. In order to 
establish such, further studies on present and additional breeds with an even gender and age 
representation should be performed. 
The study included only neutered male dogs and spayed or anoestral females. Therefore, 
potential differences in natriuretic peptide concentrations between different reproductive 
statuses could not be assessed. No consideration was given to individual variability in 
natriuretic peptide concentrations and blood was sampled only once from each dog. 
All dogs were fed commercial dog food, but differences in salt intake can have occurred, and 
this could potentially have affected blood test results.  
Sample handling was standardized, although minor differences in short-term freezing 
temperature occurred at one center. However, natriuretic peptides have been shown stable at 
the freezing temperatures used (Hunt et al., 1997, Morgenthaler et al., 2004, Mueller et al., 
2004), and all samples were analyzed in batches at the same laboratory. Hence, it is unlikely 
that this should have affected the results. 
Conclusion 
A considerable breed variation exists in concentrations of proANP 31-67 and NT-proBNP in 
healthy dogs. Further studies are warranted in order to establish breed-specific reference 
values. 
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